AIM ImmunoTech Inc. (AIM) is a publicly traded Healthcare sector company. As of August 23, 2026, AIM trades at $0.26 with a market cap of $7.87M and a P/E ratio of -0.03. AIM moved +2.09% today. Year to date, AIM is -77.11%; over the trailing twelve months it is -90.38%. Its 52-week range spans $0.06 to $20.33. Analyst consensus is buy with an average price target of $5.25. Rallies surfaces AIM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for AIM, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $0.26 |
| Market Cap | $7.87M |
| P/E Ratio | -0.03 |
| EPS | $-8.62 |
| Dividend Yield | 0.00% |
| 52-Week High | $20.33 |
| 52-Week Low | $0.06 |
| Volume | 862.02K |
| Avg Volume | 0 |
| Revenue (TTM) | $88.00K |
| Net Income | $-13.96M |
| Gross Margin | 0.00% |
2 analysts cover AIM: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $5.25.